NuCyRNA Therapeutics
PrivateLast Round
Grant
Jun 12, 2025
Total Funding Raised
$500,000
Company Overview
NuCyRNA Therapeutics is a biotechnology company developing RNA-targeting oligonucleotide therapeutics to address neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NuCyRNA Therapeutics Comparables
Compare NuCyRNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trace Neuroscience | 85% | |
| QurAlis | 76% | |
| Novartis | 68% |
NuCyRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 12, 2025 | ||||
| Seed | Oct 30, 2024 | ||||
| Accelerator | Mar 18, 2024 |
NuCyRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Harvard Innovation Labs | Accelerator |
| Target ALS | Grant |
| Ono Venture Investment, Inc. | Seed |
| Mission BioCapital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 12, 2025
Received grant from Target ALS.
- Oct 30, 2024
$500K round led by Mission BioCapital.
NuCyRNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NuCyRNA Therapeutics's valuation, stock price, and market status.
Is NuCyRNA Therapeutics a public or private company?
NuCyRNA Therapeutics is a private company.
What is the current stock price of NuCyRNA Therapeutics?
NuCyRNA Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is NuCyRNA Therapeutics worth (valuation)?
Valuation information for NuCyRNA Therapeutics is not publicly available.
Can I buy NuCyRNA Therapeutics stock?
NuCyRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NuCyRNA Therapeutics's last funding round?
NuCyRNA Therapeutics's most recent funding round was Grant on June 12, 2025.
Who are the main investors in NuCyRNA Therapeutics?
Key investors in NuCyRNA Therapeutics include Mission BioCapital.
Will NuCyRNA Therapeutics IPO soon?
No public IPO plans have been announced for NuCyRNA Therapeutics.
How can I track NuCyRNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NuCyRNA Therapeutics's secondary market activity and sign up for updates.